GSK acquires RAPT Therapeutics and restructures ViiV Healthcare partnership
GSK acquires RAPT Therapeutics for $2.2 billion to secure a new food allergy drug. The firm also retains its majority stake in ViiV as Pfizer exits the venture.
Insights:
GSK plc announced on Tuesday, January 20, 2026, a definitive agreement to acquire RAPT Therapeutics Inc , a biotechnology firm based in the United States 
US, for a total value of $2.2 billion. The United Kingdom 
GBheadquartered pharmaceutical leader will pay $58.00 per share for the acquisition, which includes an upfront investment of $1.9 billion. This strategic move is intended to bolster the respiratory, immunology, and inflammation portfolio of GSK plc.
US, for a total value of $2.2 billion. The United Kingdom GBheadquartered pharmaceutical leader will pay $58.00 per share for the acquisition, which includes an upfront investment of $1.9 billion. This strategic move is intended to bolster the respiratory, immunology, and inflammation portfolio of GSK plc.
